Case Report

Gaucher Disease - From Textbook Obscurity to Clinical Reality: A Case Report with Diagnostic and Therapeutic Implications at Moi Teaching and Referral Hospital

Abstract

Gaucher’s disease is a rare lysosomal storage disorder caused by a deficiency of the enzyme β-glucocerebrosidase, leading to progressive accumulation of glucocerebroside within macrophages. Clinical presentations vary widely, often resulting in misdiagnosis, particularly in resource-limited settings where advanced diagnostics are unavailable. A 1-year-old female presented to Moi Teaching and Referral Hospital (MTRH), Kenya, with a 2-month history of progressive, painless abdominal swelling, without fever, vomiting, jaundice, or weight loss. She had been misdiagnosed with sickle cell disease and treated with hydroxyurea, without improvement. Examination revealed pallor, massive splenomegaly (20 cm), and hepatomegaly (4 cm), with no lymphadenopathy or bone deformities. Laboratory tests showed anemia, thrombocytopenia, and
elevated LDH. Bone marrow biopsy revealed Gaucher cells, confirming Type 1 GD. The patient was managed supportively with transfusions, nutritional support, and infection prevention, and referred for enzyme assays, enzyme replacement therapy, and followup. This case highlights the diagnostic challenges in low-resource settings, where advanced enzyme assays and molecular testing are often unavailable, and treatment
options such as enzyme replacement therapy (ERT) remain inaccessible. It emphasizes the need for heightened clinical suspicion, improved diagnostic infrastructure, and advocacy for affordable therapeutic access in sub-Saharan Africa.

[1] Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441. https://doi.org/10.3390/ijms18020441
[2] Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in theOsore Ogola I et al. Gaucher Disease - From Textbook Obscurity to Clinical Reality. CRCP. 2025; 10(3):118-121 121
May/June 2025, Volume 10, Issue 3 glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567-
83. https://doi.org/10.1002/humu.20676
[3] Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372(9645):1263-71. https://
doi.org/10.1016/S0140-6736(08)61522-6
[4] Wang M, Li F, Zhang J, Lu C, Kong W. Global epidemiology of Gaucher disease: an updated systematic review and metaanalysis. J Pediatr Hematol Oncol. 2023;45(4):181-8. https://doi.org/10.1097/MPH.0000000000002506
[5] Stirnemann J, Vigan M, Hamroun D, Heraoui D, RossiSemerano L, Berger MG, et al. The French Gaucher’s disease
registry: clinical characteristics, complications, and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77. https://doi.
org/10.1186/1750-1172-7-77
[6] Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis.
2001;24:107-23. https://doi.org/10.1023/A:1012496514170
[7] Ramdin T, Schapkaitz E, Varughese S, Sevitz H, Laher F, Jacobson BF. Gaucher disease: a cause of massive splenomegaly in a15-year-old black African male. S Afr Med J. 2022;112(1):17-20. https://doi.org/10.7196/SAMJ.2022.v112i1.16011
[8] Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A. Thrombocytopenia in Gaucher disease: contribution of
hypersplenism and bone marrow infiltration. Blood Cells Mol Dis. 1999;25(4):287-94.
[9] Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic
Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160(6):603-8. https://doi.org/10.1001/
archpedi.160.6.603
[10] Essabar L, Meskini T, Lamalmi N, Ettair S, Erreimi N, Mouane N. Gaucher’s disease. Pan Afr Med J. 2015;20(1):74. https://doi.org/10.11604/pamj.2015.20.18.4112
[11] Dardis A, Michelakakis H, Rozenfeld P, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis. 2022;17:442. https://doi.org/10.1186/s13023-022-02573-6
[12] Naba A, Ettarh R, et al. Challenges in the diagnosis and management of lysosomal storage diseases in North Africa.
Orphanet J Rare Dis. 2022;17:350.
[13] Robak T, Jaroch J, Gora-Tybor J, et al. Pseudo-Gaucher cells in hematologic malignancies: report of 6 cases. Acta Haematol.2002;107(1):45-8.
[14] Yang R, Chen S, Ye J, et al. Pseudo-Gaucher cells: a diagnostic pitfall in bone marrow aspiration smears. Diagn Pathol. 2013;8:27.
[15] Murila F, Rajab JA, Ireri JM. Gaucher’s disease at a national referral hospital. East Afr Med J. 2008;85(9):455-8. https://doi.org/10.4314/eamj.v85i9.9662
[16] Mitala J, Byamugisha J, Tumwine JK. Gaucher disease in Uganda: a case report. Afr Health Sci. 2024;24(1):45-9.
[17] Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores GM, et al. Enzyme replacement therapy and
monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144(1):112-20. https://doi.org/10.1016/j.jpeds.2003.10.067
[18] Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015;90 Suppl 1:S19-24. https://doi.org/10.1002/ajh.24056
[19] Stein P, Mengel E, Hollak C, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2010;85(12):902-10.
[20] Aerts JM, Hollak C, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29(2-3):449-56. https://doi.org/10.1007/s10545-006-0272-5
[21] Ringdén O, Groth CG, Erikson A, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplant Proc. 1995;27(1):1189-91. https://doi.org/10.1097/00007890-199503000-00011
[22] Louw VJ, Fraser I, Giraldo P. Management goals of type 1 Gaucher disease in South Africa: an expert Delphi consensus document on good clinical practice. PLoS One. 2023;18(8):e0290401. https://doi.org/10.1371/journal.pone.0290401
[23] Santanakrishnan R, Dasaratha V, Munianjanappa NB, Javaregowda D, Saroja MG. Role of partial splenectomy in
Gaucher’s disease in resource challenged nations. J Indian Assoc Pediatr Surg. 2023;28(2):149-53. https://doi.org/10.4103/jiaps.jiaps_132_22
[24] Fleshner PR, Aufses AH Jr, Grabowski GA, Elias R. A 27-year experience with splenectomy for Gaucher’s disease. Am J Surg. 1991;161(1):69-75. https://doi.org/10.1016/0002-9610(91)90363-I
[25] Cox TM, Aerts JM, Andria G, et al. The role of bisphosphonates in the management of skeletal manifestations of Gaucher disease. Blood Cells Mol Dis. 2008;40(1):71-5.
Files
IssueVol 10 No 3 (2025): May-June QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/crcp.v10i3.20312
Keywords
Gaucher’s disease Lysosomal storage disorder Pediatrics Splenomegaly Enzyme replacement therapy

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ogola I, Gichemi A, Kiio M, Matendechele W, Olbara G, Muigai F. Gaucher Disease - From Textbook Obscurity to Clinical Reality: A Case Report with Diagnostic and Therapeutic Implications at Moi Teaching and Referral Hospital. CRCP. 2025;10(3):118-121.